antioxidant activity of dorzolamide/timolol fixed combination in neuroprotective therapy in glaucoma
Article Quality & Performance Metrics
Readership in this journal
SteadyRanked #1 of 43 articles by views in Neuro-Oncology
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Purpose: to study the antioxidant activity of carbonic anhydrase inhibitors and timolol fixed combinations and to compare it with other fixed combinations.
Methods: Antioxidant activity (AOA) of dorzolamide/timolol (Cosopt), dorzolamide/timolol (Dorzopt Plus), latanoprost/timolol, brimonidine/timolol, travoprost/timolol and bimatoprost/timolol fixed combinations was measured in vitro using the model of oxida- tive hemolysis.
Results: Dorzolamide/timolol (Cosopt) AOA was higher than that of other fixed combinations and increased with the quantity of the drugs added to the model system: 40%, 52% and 75% in 30 μl, 60 μl and 90 μl respectively.
Conclusion: these findings suggest that dorzolamide/timolol fixed combination has potential advantages over the other fixed combinations due to its high antioxidant activity and might be used as the neuroptotective agent for glaucoma treatment.
| Reference Key |
kurysheva2014oftalmologiantioxidant
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;N. I. Kurysheva;O. A. Azizova;A. P. Piryazev |
| Journal | Neuro-Oncology |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.